BI 1701963
As of the edition of 20 October 2026, BI 1701963 is a drug known only by a code name: in active development; acts on KRAS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Code name only
- Registered trials
- 6, 3 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of BI 1701963.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KRAS | GTPase KRas | P01116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 0 | 3 | 3 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2019 to now |
| Amgen | Lead sponsor of trials | 2019 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2021 to now |